NCT05215067View on ClinicalTrials.gov

A Phase II Trial of AK104 in Advanced Non-Small Cell Lung Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

March 9, 2022

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2026

Conditions
Advanced Non-small Cell Lung Cancer
Interventions
DRUG

AK104

IV infusion,Specified dose on specified days

DRUG

Docetaxel

IV infusion,Specified dose on specified days

Trial Locations (1)

210009

Jiangsu Cancer Hospital, Nanjing

Sponsors

Lead Sponsor

Akeso
All Listed Sponsors
lead

Akeso

INDUSTRY

NCT05215067 - A Phase II Trial of AK104 in Advanced Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter